Industry Sponsored Sessions

​​​Wednesday, March 1, 2017​

13:00-14:30 - Auditorium I

Session Supported by Roche


HPV Primary Screening and Beyond: Improving Patient Outcomes Around the World 
  • Update From the Canadian Cervical Cancer Screening Trial (CCCaST) and Insights
    Into Screening Practices Around the World
    Eduardo Franco, Canada
  • Cervical Cancer Screening in South Africa: Where Are We Now?
    Chris Maske, South Africa
  • Being Certain We Get the Diagnosis Correct for Our Patients:
    The CERTAIN Study Results
    Mark H. Stoler, USA

Thursday, March 2, 2017

Meeting Room 1.43

Session Supported by

Breakfast Satellite (Breakfast bags will be provided)

Philip Castle, USA
Anna-Lise Williamson, South Africa

Utility of Xpert® HPV for Cervical Cancer Screening of HIV-Positive Women
Louise Kuhn, USA

Practical Considerations Around Using Xpert® HPV in Low Income Countries,
Focusing on Malawi
Heather Cubie, UK

HPV Diagnostic Testing Under the New Australian National Cervical
Screening Program, Including Self-Collection
David Hawkes, Australia

Point-of-Care HPV Testing for Cervical Screening in High-Buden,
Low-income Settings
Andrew Vallely, Australia

Dr. Castle, Dr. Vallely, and Dr. Hawkes are independent participants in this event who have
not, nor will receive any form form of compensation from Cepheid.

13:30-15:00​ - Auditorium II

Session Supported by Hologic 


Preventing HPV related cancers globally: Specific tools and strategies

Chairperson: Hennie Botha, South Africa

- Introduction & cervical cancer screening in Africa

Hennie Botha, Stellenbosch University Cape Town, South Africa

- The use of HPV oncogenic E6/E7 mRNA for cancer screening in HIV infected populations and beyond

John-Paul Bogers, University of Antwerp, Antwerp, Belgium

- Performance of HPV tests in screening young vaccinated women: Results of the SHEVA study

Ramya Bhatia, University of Edinburgh, Edinburgh, UK

-Searching for the right combinations of vaccination and screening for cervical cancer prevention: The HPV FASTER project

Xavier Bosch, Institut Catala d'Oncologia, Barcelona, Spain

-Discussion and Questions

Friday​, march 3, 2017

07:50-09:20 - Auditorium II

Session supported by GSK/Aspen


Spotlight on Cervical Cancer prevention: HPV vaccination in South Africa and beyond

Welcome and Introduction
Dr. Olakunle Oladehin

Expert Panel Discussion
Dr. Olakunle Oladhehin
Prof. Lynette Denny 
Prof. Hennie Botha
Dr. Valérie Berlaimont
Dr. Martin Ryser

Concluding Remarks and QA
Dr. Olakunle Oladehin

12:40-14:10 - Ballroom West

Supported through an independent educational grant from Merck & Co., Inc., Kenilworth, NJ, USA


The Story of HPV: Yesterday, Today, and Tomorrow

Activity Overview: Healthcare providers in multiple disciplines worldwide are in unique positions to leave a powerful legacy of cancer prevention in the hundreds of thousands of children and young adults they care for. In this symposium, an international panel of experts will weave the story of HPV prevention – past, present, and future – with a focus on what we've learned, what works, and lessons on advocacy from clinic to national health programs.

Chair: Kenneth A. Alexander, MD, PhD (United States) 

Panel: Phionah L. Atuhebwe, MBChB, MPH (Uganda), Stephen Goldstone, MD (United States), Margaret Stanley, MB, PhD (United Kingdom)

Welcome and Introduction
Kenneth A. Alexander

Historical Perspective: From Hypothesis to Discovery
Margaret Stanley

Recent Developments
Kenneth A. Alexander

HPV in Males: What Have We Learned?
Stephen Goldstone

Implementation Progress & Woes
Kenneth A. Alexander

The Imbalance of Disease: HPV in the Developing World
Phionah L. Atuhebwe

Vaccine Safety Scares: Fact or Fiction?
Margaret Stanley

Overcoming Barriers and Challenges
Kenneth A. Alexander

Questions & Answers

Closing Remarks
Kenneth A. Alexander

To pre-register for the symposium please click here​

17:30-19:00 - Ballroom West

Session supported by BD


Cervical Cancer Screening and HPV genotyping: 
New Results from the BD Onclarity US Registration trial and Danish Self Sampling study

Symposium Chair
Dr. Judith Whittaker

Balancing Prevalence vs. Risk for CIN3+ by HPV Genotype: Perspectives from the BD Onclarity HPV Clinical Trial
Mark H Stoler

Performance of the BD Onclarity HPV Assay in Women 25+ Years Enrolled in the US Registration Trial
Thomas C. Wright

HPV Self-sampling for Non-attenders in Denmark: From Pilot to 2017 Implementation
Jesper Bonde

Keep Me Updated